XML 49 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Collaborative Research and Development Agreements - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended			9 Months Ended	1 Months Ended	3 Months Ended				9 Months Ended			9 Months Ended	12 Months Ended		1 Months Ended		3 Months Ended		9 Months Ended									1 Months Ended
	Aug. 31, 2014	Dec. 31, 2011	Oct. 31, 2011 Amendment	Mar. 31, 2014 Amendment Advance the program following completion of Phase 2a	Dec. 31, 2012 Amendment Advance the program following completion of Phase 2a	Mar. 31, 2012 Amendment Advance the program following completion of Phase 2a	Sep. 30, 2014 Maximum Amendment Advance the program following completion of Phase 2a	Dec. 31, 2008 Glaxo, Smith, Kline	Sep. 30, 2014 Glaxo, Smith, Kline	Jun. 30, 2014 Glaxo, Smith, Kline	Mar. 31, 2014 Glaxo, Smith, Kline	Sep. 30, 2013 Glaxo, Smith, Kline	Sep. 30, 2014 Glaxo, Smith, Kline	Sep. 30, 2013 Glaxo, Smith, Kline	Dec. 31, 2013 Glaxo, Smith, Kline	Sep. 30, 2014 Glaxo, Smith, Kline Maximum	Dec. 31, 2013 Glaxo, Smith, Kline Minimum	Dec. 31, 2011 Glaxo, Smith, Kline Expansion	Oct. 31, 2011 Astra Zeneca	Sep. 30, 2006 Astra Zeneca	Sep. 30, 2014 Astra Zeneca	Sep. 30, 2013 Astra Zeneca	Sep. 30, 2014 Astra Zeneca	Sep. 30, 2013 Astra Zeneca	Dec. 31, 2013 Astra Zeneca	Aug. 31, 2014 National Institutes of Health	Sep. 30, 2013 National Institutes of Health Hepatic Fibrosis and Cirrhosis	Jun. 30, 2012 National Institutes of Health Autoimmune Disease	May 31, 2012 National Institutes of Health Rheumatoid Arthritis	Jul. 31, 2011 National Institutes of Health Skin Autoimmune Inflammation	Aug. 31, 2010 National Institute Of Allergy And Infectious Diseases HBV	Sep. 30, 2008 National Institute Of Allergy And Infectious Diseases ISS Technology
Product Information [Line Items]
Collaboration Revenue			$ 3,000,000	$ 5,400,000	$ 6,000,000	$ 2,600,000		$ 10,000,000	$ 631,000			$ 357,000	$ 1,893,000	$ 1,071,000							$ 180,000	$ 180,000	$ 540,000	$ 540,000
Revenue from milestone payment		12,000,000					100,000,000											3,000,000			309,000	573,000	1,741,000	1,738,000
Deferred revenue recognition period																7 years	6 years		50 months				24 months
Additional revenue recognized									300,000	300,000	300,000
Deferred revenue									600,000				600,000		2,500,000						5,900,000		5,900,000		4,800,000
Research collaboration and license agreement period																				3 years
Number of healthy workers placeebo was delivered by inhalation	45
Description of doses well tolerated	15.4 mg/week
Grants receivable																										200,000	200,000	600,000	400,000	600,000	1,400,000
Contract agreement period																																5 years
Contract awarded to develop technology																																$ 17,000,000

X

- Definition

Contract term.

+ References

No definition available.

+ Details

Name:	dvax_ContractTerm
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Description of doses well tolerated

+ References

No definition available.

+ Details

Name:	dvax_DescriptionOfDosesWellTolerated
Namespace Prefix:	dvax_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of healthy workers placeebo was delivered by inhalation

+ References

No definition available.

+ Details

Name:	dvax_NumberOfHealthyWorkersPlaceeboWasDeliveredByInhalation
Namespace Prefix:	dvax_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research collaboration and license agreement period.

+ References

No definition available.

+ Details

Name:	dvax_ResearchCollaborationAndLicenseAgreementPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Revenue recognition period.

+ References

No definition available.

+ Details

Name:	dvax_RevenueRecognitionPeriod
Namespace Prefix:	dvax_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 910

-SubTopic 310

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c

-Article 5

+ Details

Name:	us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name:	us-gaap_GrantsReceivable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of revenue recognized in earnings during the reporting period associated with arrangements entered into or modified after adoption of the new accounting pronouncement or change in accounting principle.

+ References

No definition available.

+ Details

Name:	us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCurrentPeriodDisclosuresRevenueRecognizedAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_ProductInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration